TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expre
3 months ago
- #non-small cell lung cancer
- #immunotherapy
- #clinical trial
- TROPION-Lung10 is a phase 3 study evaluating datopotamab deruxtecan (Dato-DXd) plus rilvegostomig versus pembrolizumab in treatment-naïve nonsquamous NSCLC patients with high PD-L1 expression (≥50%) and no actionable genomic alterations.
- The study aims to address primary or acquired resistance to PD-(L)1 inhibitors by combining a TROP2-directed antibody-drug conjugate (Dato-DXd) and a bispecific anti-PD-1/anti-TIGIT antibody (rilvegostomig).
- Approximately 675 patients will be randomized (2:1:2) to receive Dato-DXd + rilvegostomig, rilvegostomig alone, or pembrolizumab, with dual primary endpoints of progression-free survival (PFS) and overall survival (OS) in the TROP2 biomarker-positive population.
- Secondary endpoints include objective response rate, duration of response, PFS2, patient-reported outcomes, and safety assessments.
- The study is sponsored by AstraZeneca, with Daiichi Sankyo collaborating on datopotamab deruxtecan development.